Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 3 |
| List of Tables | 4 | 1 |
| List of Figures | 4 | 1 |
| Introduction | 5 | 1 |
| Global Markets Direct Report Coverage | 5 | 1 |
| Galectin-1 (Gal-1 or Lactose-Binding Lectin 1 or 14 kDa Laminin-Binding Protein) Overview | 6 | 1 |
| Therapeutics Development | 7 | 4 |
| Galectin-1 (Gal-1 or Lactose-Binding Lectin 1 or 14 kDa Laminin-Binding Protein) Products under Development by Stage of Development | 7 | 1 |
| Galectin-1 (Gal-1 or Lactose-Binding Lectin 1 or 14 kDa Laminin-Binding Protein) Products under Development by Therapy Area | 8 | 1 |
| Galectin-1 (Gal-1 or Lactose-Binding Lectin 1 or 14 kDa Laminin-Binding Protein) Products under Development by Indication | 9 | 2 |
| Galectin-1 (Gal-1 or Lactose-Binding Lectin 1 or 14 kDa Laminin-Binding Protein) Pipeline Products Glance | 11 | 2 |
| Late Stage Products | 11 | 1 |
| Early Stage Products | 12 | 1 |
| Galectin-1 (Gal-1 or Lactose-Binding Lectin 1 or 14 kDa Laminin-Binding Protein) Products under Development by Companies | 13 | 2 |
| Galectin-1 (Gal-1 or Lactose-Binding Lectin 1 or 14 kDa Laminin-Binding Protein) Products under Development by Universities/Institutes | 15 | 2 |
| Galectin-1 (Gal-1 or Lactose-Binding Lectin 1 or 14 kDa Laminin-Binding Protein) Therapeutics Assessment | 17 | 7 |
| Assessment by Monotherapy/Combination Products | 17 | 1 |
| Assessment by Mechanism of Action | 18 | 2 |
| Assessment by Route of Administration | 20 | 2 |
| Assessment by Molecule Type | 22 | 2 |
| Galectin-1 (Gal-1 or Lactose-Binding Lectin 1 or 14 kDa Laminin-Binding Protein) Companies Involved in Therapeutics Development | 24 | 2 |
| Galectin Therapeutics, Inc. | 24 | 1 |
| PepTx, Inc. | 25 | 1 |
| Galectin-1 (Gal-1 or Lactose-Binding Lectin 1 or 14 kDa Laminin-Binding Protein) Drug Profiles | 26 | 18 |
| CNC-225 Drug Profile | 26 | 1 |
| GM-CT-01 Drug Profile | 27 | 4 |
| GRMD-02 Drug Profile | 31 | 10 |
| Monoclonal Antibody to Inhibit Galectin-1 for B-Cell Non-Hodgkin Lymphoma Drug Profile | 41 | 1 |
| PTX-013 Drug Profile | 42 | 1 |
| Recombinant Protein to Activate Gal-1 for Immunology Drug Profile | 43 | 1 |
| Galectin-1 (Gal-1 or Lactose-Binding Lectin 1 or 14 kDa Laminin-Binding Protein) Dormant Projects | 44 | 1 |
| Galectin-1 (Gal-1 or Lactose-Binding Lectin 1 or 14 kDa Laminin-Binding Protein) Discontinued Products | 45 | 1 |
| Galectin-1 (Gal-1 or Lactose-Binding Lectin 1 or 14 kDa Laminin-Binding Protein) Featured News &Press Releases | 46 | 13 |
| Jun 02, 2016: Galectin Therapeutics Announces Positive Preclinical Results on the Role of Galectin-3 in Mediating Vascular Remodeling in Pulmonary Arterial Hypertension | 46 | 1 |
| May 16, 2016: Galectin Therapeutics Announces Positive Interim Results from Phase 2a Trial with GR-MD-02 in Moderate-to-Severe Plaque Psoriasis | 46 | 1 |
| May 11, 2016: Galectin Therapeutics Announces Complete Enrollment in its Phase 2 Trial with GR-MD-02 in NASH Patients with Advanced Fibrosis | 47 | 1 |
| May 05, 2016: Preclinical Research on the Role of Galectin-3 in Pulmonary Arterial Hypertension to be Presented at the American Thoracic Society 2016 International Conference | 48 | 1 |
| Feb 24, 2016: Galectin Therapeutics Receives U.S. Patent Allowance for GR-MD-02 to Treat Pulmonary Fibrosis | 48 | 1 |
| Jan 07, 2016: Galectin Therapeutics Posts "2015-2016, Progress and Possibilities" to Corporate Website | 49 | 2 |
| Nov 11, 2015: Research Underlying Galectin's Development of GR-MD-02 in Cancer Presented at the Society for Immunotherapy of Cancer Annual Meeting | 51 | 1 |
| Oct 19, 2015: Galectin Therapeutics' GR-MD-02 to be Studied in Combination With Keytruda in Patients With Metastatic Melanoma | 52 | 1 |
| Sep 24, 2015: Galectin Therapeutics Begins Phase 2a Psoriasis Study With GR-MD-02 | 53 | 1 |
| Sep 16, 2015: Galectin Therapeutics Announces Start of Phase 2 Clinical Trial With GR-MD-02 in NASH With Advanced Fibrosis | 53 | 1 |
| Aug 13, 2015: Galectin Therapeutics Receives U.S. Patent Notice of Allowance for Use of Pectin Compounds to Reduce Fibrosis in Multiple Diseases | 54 | 1 |
| Aug 03, 2015: Exalenz Bioscience Announces Collaboration with Galectin Therapeutics to use BreathID to Monitor Patients with Cirrhosis Associated with NASH | 55 | 1 |
| Jun 29, 2015: Galectin Therapeutics Initiates Enrollment for GR-MD-02 Phase 2 Clinical Trial in NASH with Cirrhosis | 55 | 2 |
| May 14, 2015: Galectin Therapeutics Reports no Drug-Drug Interaction Between GR-MD-02 and Midazolam | 57 | 1 |
| Mar 24, 2015: Galectin Therapeutics Presented Research With GR-MD-02 at the American Association for the Study of Liver Diseases Industry Colloquium | 58 | 1 |
| Appendix | 59 | 2 |
| Methodology | 59 | 1 |
| Coverage | 59 | 1 |
| Secondary Research | 59 | 1 |
| Primary Research | 59 | 1 |
| Expert Panel Validation | 59 | 1 |
| Contact Us | 59 | 1 |
| Disclaimer | 60 | 1 |